PCI148 IDENTITY, SYMPTOMS AND IMPACTS EXPERIENCED BY MEN WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Moise P1, Tomaszewski E2, Kruptof R3, Baskin-Rey E4, Meyer M5, Holstrom S1
1Quintiles Consulting, Cambridge, MA, USA, 2Astellas Pharma Global Development, Leiden, The Netherlands, 3Astellas Pharma Europe, Leuderyd, The Netherlands
OBJECTIVES: We sought to identify the most relevant and important symptoms and impacts of non-metastatic (M0) castration resistant prostate cancer (CRPC) from the patient’s perspective. METHODS: First, a literature review was performed that focused on symptoms related to living with M0 CRPC. Then, individual interviews with 17 M0 CRPC patients were conducted following a semi-structured interview guide. Patients were asked about symptoms, impacts of living with M0 CRPC, and interference of symptoms higher than a six on the impact scale. The most common symptoms mentioned included: need to plan for urinary frequency (n=9), interference with daily activities (n=8), and anxiety (n=7) or frustration (n=7) over the diagnosis, symptoms, or treatment. Clinicians confirmed the symptoms expressed by patients and rated that most of these will be attributed to prior and/or current treatments for PC and not the PC itself, a finding observed consistently in the published literature. CONCLUSIONS: The most relevant and important symptoms (erectile dysfunction, anxiety, and emotional impacts) expressed by patients aligned with those mentioned by clinicians and the literature. This data provides valuable insight into patients’ experience with M0 CRPC illustrating that the most relevant symptoms and impacts thereof may be attributed to PC therapy and not to the consequences of the M0 CRPC disease state itself.

PCI149 ASSESSMENT OF RESPONSE SHIFT AND TRUE CHANGE USING STRUCTURAL EQUATION MODELING FOR HEALTH-RELATED QUALITY-OF-LIFE SCORES IN PATIENTS WITH BREAST CANCER AFTER SURGERY
Nakazato K1, Shirouma K1, Sunokura Y1, Fuku H1, Shibahara H1, Saito S1
1Ritsumeikan University, Kusatsu, Japan, 2Tokoh University, Seidai, Japan, 3Okayama University Hospital, Okayama, Japan, 4National Institute of Public Health, Saitama, Japan, 5Okayama University, Okayama, Japan
OBJECTIVES: Response shift can be considered measurement bias in the assessment of HRQOL. The purpose of this study was to detect response shift and true change in health-related quality-of-life (HRQOL) scores in patients with breast cancer after surgery. METHODS: The HRQOL data set was derived from published in the ‘Breast Cancer Res Treat’ in 2016. The factors developed in this study based on ‘four domains’ and ‘higher concept’ yielded more differentiating one drug over another through an improvement demonstrated using PROs instruments. The factors included socio-demographic, clinical and survey characteristics. RESULTS: The analyses using the models developed in this study based on ‘four domains’ and ‘higher concept’ yielded more easily interpretable results compared to previously reported models based on ‘items’ and ‘domains’. The results of this study will help understand possible measurement bias due to response shift effects on the assessment of HRQOL in a longitudinal study.

PCI150 DESIGN AND VALIDATION OF A QUESTIONNAIRE FOR MEASURING PERCEIVED RISK OF SKIN CANCER
Morales-Sánchez MA1, Ferialta-Pedrero ML2
1Centro Dermatológico “Dr. Ladulás de la Pausca”, Secretaría de Salud del D.F., Distrito Federal, Mexico, 2Centro Dermatológico “Dr. Ladulás de la Pausca”, Secretaría de Salud del D.F., Distrito Federal, Mexico
OBJECTIVES: The aim of this study was to design and validate a self-administered questionnaire for measuring the perceived risk of skin cancer. METHODS: A self-administered questionnaire with a visual Likert-type scale was designed based on the results of the analysis of the content of a survey performed in 100 patients in the Dr. Ladulás Melanoma Clinic. Distractibility of the questionnaire was assessed. RESULTS: The final questionnaire had 18 items. The internal consistency measured with Cronbach alpha was 0.824 overall. In the factor analysis, 4 factors (denoted as affective, behavioral, severity, and susceptibility) and an indicator of risk accounted for 65.13% of the variance. CONCLUSIONS: The scores obtained in this questionnaire would be appropriate for measuring the perception of risk in adults (aged 18 years or more) who attended the dermatology clinic. This is the first questionnaire in Spanish to measure perceived risk of skin cancer that serves to quantify the response to interventions for preventing this disease.

PCI151 REPORTED OUTCOMES IN CASTRATION-RESISTANT PROSTATE CANCER
Apprawal S, Segal P
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: Patient-reported outcomes (PROs) are becoming useful tools for collecting and generating evidence for new medical products to show improvements in health-related quality of life (HRQOL). Castration-Resistant Prostate Cancer (CRPC) is a chronic disease with high importance for patient HRQOL. The objective of this study was to review, analyze, and understand trends in the PRO instruments used in patients with CRPC. METHODS: A systematic literature search for CRPC randomized controlled trials (RCTs) with PROs endpoints was undertaken for the databases PubMed, Cochrane, Embase, and Scopus. Data was collected for the study size, interventions, year, PRO instrument, and results for PROs. Analysis was conducted to identify trends in commonly used PRO instruments and differences in measured patient response to PC therapy and not to the consequences of the M0 CRPC disease state itself.

PCI152 IMPACT OF COLORECTAL CANCER ON ACTIVITIES OF DAILY LIVING AND DEPRESSIVE RISK AMONG OLDER AMERICANS
Quach C1, Sanoff HK2, Williams GR3, Lyons JC4, Reeve BB5
1Stony Brook University, North Carolina at Chapel Hill, Chapel Hill, NC, USA
OBJECTIVES: 1) Estimate change in activities of daily living (ADL) and risk for major depressive disorder (MDD) among older Americans >64 following years diagnosis and treatment of colorectal cancer (CRC); 2) Compare change in ADL function and MDD symptom change in CRC patients to matched controls. METHODS: This population-based study used the Surveillance, Epidemiology, and End Results–Medicare Health Outcomes Survey (SEER-MHOS) dataset (1998-2007). Medicare managed care beneficiaries diagnosed with CRC between April 1, 2001 and follow-up MHOS (n=349) were matched to non-cancer controls (n=1,745) using propensity scores. Analysis of covariance models estimated change in ability to perform six ADLs: bathing, dressing, eating, getting in or out of chairs, walking, using the toilet. Logistic regression was used to estimate MDD risk. Covariates included socio-demographic, clinical and survey characteristics. RESULTS: Mean time from diagnosis to MHOS follow-up was 12.1 months (SD 9.8) for CRC patients (n=1,031 Stage I, 122 Stage II, 95 Stage III, 29 Stage IV); 2742 through patients and controls reported similar ADL impairment at baseline (97 vs. 92; p=0.06). CRC patients had greater impairment at follow-up (mean 2.21 vs. 92; p<0.01). Mean increase in ADL impairment was 1.02 for Stage I, 1.25 for Stage II, 1.53 for Stage III, and 1.67 for Stage IV compared to controls. CRC patients experienced greater improvement with respect to bathing (p<0.01), getting in/out of chairs (p<0.01) and walking (p=0.01). CRC patients and controls had similar MDD risk at baseline (OR 1.3 of 3.95) and follow-up (OR 3.18 95% CI 1.22-1.58) and at follow-up (OR 3.18 95%. CONCLUSIONS: CRC has adverse effects on ADL functioning among older Americans—even in the early, curable stages. This study informs clinicians and caregivers of the need to identify opportunities to provide supportive care for patients’ basic needs of self-care.

PCI154 THE REAL IMPACT OF QUALITY OF LIFE (QOL) ENDPOINTS ON MARKET ACCESS DECISIONS ACROSS MARKETS – A CASE STUDY OF ONCOLOGY PRODUCTS
Gardiner RB1, Sealey S2, Edahodou A3, Mukku SR4
OBJECTIVES: Recent approvals of targeted oncology therapies have resulted in increased patient survival, and potential commoditization. Subsequently, a greater emphasis has been placed on QoL, and PRO endpoints. However, the impact of QoL instruments on market access of new oncology products remains unclear. This research aims at understanding the true relevance of QoL endpoints in payer decision making. METHODS: The research was conducted through in-depth secondary research and interviews with payers in 6 countries including the US, Germany, France, Spain, Italy, and Sweden. RESULTS: In the markets studied, QoL data is a requirement to be submitted for reimbursement; however, it is not a key determinant of reimbursement or pricing decisions at a national level. Some countries like Italy and Spain view QoL data as being important at a regional and local level for inclusion in formularies and guidelines. Furthermore, payers suggest that QoL is considered in a qualitative sense based on the safety profile of a drug, and do not use QoL to assess treatment benefit. For example, in Sweden, the TUV requires the use of general PRO instruments such as EQ-5D that are validated to be used in cost/QALY calculations, unlike disease specific instruments. CONCLUSIONS: Contrary to the increasing academic interest in QoL and PRO endpoints, these have not yet translated into playing a significant role in payer decision making for new oncology products. Currently, QoL instruments are used in oncology clinical trials as standard protocol. However, differentiating one drug over another through an improvement demonstrated using QoL instruments does not yet directly translate to an advantage from a market access point of view for that drug.